In vitro assessment of P-glycoprotein-mediated antiseizure medications efflux in a blood–brain barrier cell model
Journal of Pharmacy and Pharmacology · 2026
DOI: 10.1093/jpp/rgaf099 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2026. Verfasst von Priyanka Rani Paul und 5 weiteren Autor:innen. Beteiligte Einrichtung: Genomics and Molecular Medicine Unit, Institute of Genomics and Integrative Biology (IGIB), Council of Scientific and Industrial Research (CSIR), Mal…. Hauptthemen laut MEDLINE: Blood-Brain Barrier, Anticonvulsants, ATP Binding Cassette Transporter, Subfamily B, Member 1. Die Arbeit nennt 80 Literaturangaben. Gefördert von: CSIR-Institute of Genomics and Integrative Biology.
Abstract (Originalsprache)
Objectives
Drug-resistant epilepsy affects 30% of patients, where antiseizure medications (ASMs) are non-effective. A possible mechanism is the presence of the P-glycoprotein (P-gp) transporter in the blood–brain barrier (BBB), which may cause ASM efflux and limit bioavailability. Therefore, this study aimed to evaluate the potential of ASMs as P-gp substrates.
Methods
The study was conducted using the BBB model cell line human cerebral microvascular endothelial cells (hCMEC/D3). Ten widely used ASMs were assessed for their interaction with P-gp through in vitro assays: ATPase, competitive substrate efflux, and bidirectional transport assay, followed by quantification using HPLC or liquid chromatography-tandem mass spectrometry. Key findings Valproic acid, lamotrigine, and topiramate stimulated basal ATPase activity of P-gp. In a competitive substrate efflux assay, valproic acid, lamotrigine, and topiramate increased rhodamine123 intracellular accumulation, thereby influencing its P-gp-mediated efflux. Valproic acid and lamotrigine exhibited an efflux ratio > 1.5 in a bidirectional transport assay, which was significantly reduced in the presence of a P-gp inhibitor (P < .01).
Conclusions
The findings support that valproic acid and lamotrigine are likely substrates of P-gp at the BBB. Thus, targeting the P-gp-mediated efflux may represent a promising strategy for managing drug-resistant epilepsy against these ASMs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Genomics and Molecular Medicine Unit, Institute of Genomics and Integrative Biology (IGIB), Council of Scientific and Industrial Research (CSIR), Mall Road, Delhi 110007, India.
- Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India.
- Department of Biotechnology, Delhi Technological University, Shahbad Daulatpur, Main Bawana Road, Delhi 110042, India.
- Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India.
ORCID-Profile: Ritushree Kukreti
Förderung
- CSIR-Institute of Genomics and Integrative Biology
Zitieren
APA
Paul, P. R., Bora, S., Srivastava, A., Kukal, S., Mishra, M. K., & Kukreti, R. (2026). In vitro assessment of P-glycoprotein-mediated antiseizure medications efflux in a blood–brain barrier cell model. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgaf099
Vancouver
Paul PR, Bora S, Srivastava A, Kukal S, Mishra MK, Kukreti R. In vitro assessment of P-glycoprotein-mediated antiseizure medications efflux in a blood–brain barrier cell model. Journal of Pharmacy and Pharmacology. 2026. doi:10.1093/jpp/rgaf099
BibTeX
@article{Paul2026,
author = {Paul, Priyanka Rani and Bora, Shivangi and Srivastava, Ankit and Kukal, Samiksha and Mishra, Manish Kumar and Kukreti, Ritushree},
title = {In vitro assessment of P-glycoprotein-mediated antiseizure medications efflux in a blood–brain barrier cell model},
journal = {Journal of Pharmacy and Pharmacology},
year = {2026},
doi = {10.1093/jpp/rgaf099}
}
EUVIMED